SMT201600259B - Composizioni farmaceutiche antibatteriche - Google Patents

Composizioni farmaceutiche antibatteriche

Info

Publication number
SMT201600259B
SMT201600259B SM201600259T SM201600259T SMT201600259B SM T201600259 B SMT201600259 B SM T201600259B SM 201600259 T SM201600259 T SM 201600259T SM 201600259 T SM201600259 T SM 201600259T SM T201600259 B SMT201600259 B SM T201600259B
Authority
SM
San Marino
Prior art keywords
pharmaceutical compositions
antibacterial
compositions antibacterial
pharmaceutical
compositions
Prior art date
Application number
SM201600259T
Other languages
English (en)
Inventor
Francis Xavier Wilson
Peter David Johnson
Richard Vickers
Richard Storer
Graham Michael Wynne
Alan Geoffrey Roach
Moor Olivier De
Colin Richard Dorgan
Paul James Davis
Original Assignee
Summit Therapeutics Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Therapeutics Plc filed Critical Summit Therapeutics Plc
Publication of SMT201600259B publication Critical patent/SMT201600259B/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
SM201600259T 2008-12-02 2016-08-03 Composizioni farmaceutiche antibatteriche SMT201600259B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0821913.1A GB0821913D0 (en) 2008-12-02 2008-12-02 Antibacterial compounds
PCT/GB2009/002792 WO2010063996A2 (en) 2008-12-02 2009-12-01 Antibacterial compounds

Publications (1)

Publication Number Publication Date
SMT201600259B true SMT201600259B (it) 2016-08-31

Family

ID=40262471

Family Applications (2)

Application Number Title Priority Date Filing Date
SM201500117T SMT201500117B (it) 2008-12-02 2015-05-18 Composti antibatterici
SM201600259T SMT201600259B (it) 2008-12-02 2016-08-03 Composizioni farmaceutiche antibatteriche

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SM201500117T SMT201500117B (it) 2008-12-02 2015-05-18 Composti antibatterici

Country Status (27)

Country Link
US (3) US8975416B2 (it)
EP (3) EP2907813B1 (it)
JP (3) JP5665756B2 (it)
KR (1) KR101643435B1 (it)
CN (1) CN102227411B (it)
AU (1) AU2009323854B2 (it)
BR (2) BR122020013025B1 (it)
CA (1) CA2744962C (it)
CY (2) CY1116383T1 (it)
DK (2) DK2907813T3 (it)
ES (2) ES2537059T3 (it)
GB (1) GB0821913D0 (it)
HR (2) HRP20150518T1 (it)
HU (1) HUE029151T2 (it)
IL (1) IL213325A (it)
LT (1) LT2907813T (it)
MX (1) MX2011005837A (it)
NZ (1) NZ593111A (it)
PL (2) PL2373631T3 (it)
PT (2) PT2907813T (it)
RS (1) RS54904B1 (it)
RU (1) RU2525915C2 (it)
SG (1) SG171939A1 (it)
SI (2) SI2373631T1 (it)
SM (2) SMT201500117B (it)
WO (1) WO2010063996A2 (it)
ZA (1) ZA201103751B (it)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
GB2480813A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
WO2011151619A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
GB2480816A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of Clostridium difficile associated diseases
GB2480814A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
WO2011151620A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
SI2575968T1 (sl) * 2010-06-01 2016-06-30 Summit Therapeutics Plc Spojine za zdravljenje bolezni, ki je povezana s clostridium difficile
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
DK3628161T3 (da) 2012-11-23 2023-05-30 Seres Therapeutics Inc Synergistiske bakterielle sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
AU2014212004B2 (en) 2013-02-04 2018-09-20 Société des Produits Nestlé S.A. Compositions for treating or preventing or reducing the severity of clostridium difficile related diseases
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
EP2967077A4 (en) 2013-03-15 2016-09-14 Seres Therapeutics Inc NETWORK-BASED MICROBIAL COMPOSITIONS AND METHOD
KR102611070B1 (ko) 2013-11-25 2023-12-07 세레스 테라퓨틱스, 인코포레이티드 상승적 박테리아 조성물 및 그것의 생산 방법 및 용도
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
JP6526956B2 (ja) * 2013-12-19 2019-06-05 花王株式会社 固形状組成物
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
US20180000793A1 (en) 2015-02-06 2018-01-04 Ernesto Abel-Santos Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis
MX2020001774A (es) 2017-08-14 2020-09-09 Seres Therapeutics Inc Composiciones y métodos para tratar enfermedad colestásica.
EP3692030B1 (en) * 2017-10-05 2023-04-19 Sandoz AG Process for the preparation of ridinilazole using acid addition salts
BR112020008552A2 (pt) 2017-10-30 2020-12-29 Seres Therapeutics, Inc. métodos e composições para tratamento de resistência a antibiótico
MX2022000598A (es) 2019-07-17 2022-03-04 Summit Oxford Ltd Preparacion de compuestos antibacterianos.
DK4069691T3 (da) 2019-12-06 2024-10-28 Vertex Pharma Substituerede tetrahydrofuraner som modulatorer af natriumkanaler
US20210324009A1 (en) * 2020-04-17 2021-10-21 The University Of Hong Kong Anti-bacterial calcium-dependent antibiotic (cda) analogs and methods of treating bacterial infections
GB202100471D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
GB202100470D0 (en) * 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
MX2023013980A (es) * 2021-05-24 2024-03-05 Aimmax Therapeutics Inc Combinaciones de pristinamicina ia y flopristin para el tratamiento o prevencion de infecciones bacterianas.
MA64853B1 (fr) 2021-06-04 2025-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hétéro)aryl) tétrahydrofuran carboxamides utilisés en tant que modulateurs de canaux sodiques
JP7728367B2 (ja) 2021-06-14 2025-08-22 スコーピオン・セラピューティクス・インコーポレイテッド がんを処置するために使用され得る尿素誘導体
WO2023039159A2 (en) 2021-09-09 2023-03-16 Abel Santos Ernesto Inhibitors of c. difficile spore germination
WO2024112631A1 (en) * 2022-11-22 2024-05-30 Aimmax Therapeutics, Inc. Streptogramin a monotherapy for treating or preventing bacterial infections
EP4418810A1 (de) 2023-02-15 2024-08-21 Siemens Aktiengesellschaft Verfahren zur rechnergestützten überwachung einer industriellen anlage mittels eines funknetzes

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3661849A (en) * 1965-10-06 1972-05-09 Ashland Oil Inc Heterocyclic polyimides prepared from heterocyclic diamines
US3503929A (en) 1965-10-21 1970-03-31 Minnesota Mining & Mfg Polyimidazoquinazolines and polyamidobenzimidazoles
DE1670684A1 (de) 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
US4087409A (en) * 1966-11-07 1978-05-02 Monsanto Company Ordered heterocyclic copolymers
JPS50140445A (it) * 1974-04-30 1975-11-11
JPS50154250A (it) * 1974-05-31 1975-12-12
JPH03500661A (ja) * 1988-06-09 1991-02-14 ザ・ダウ・ケミカル・カンパニー ベンゾキサゾール,ベンゾチアゾールまたはベンズイミダゾールの少なくとも1つの結合によって架橋したビスシクロブタレンのモノマー,オリゴマー及びポリマー
US5089592A (en) 1988-06-09 1992-02-18 The Dow Chemical Company Biscyclobutarene monomer comprising two cyclobutarene moieties bridged by a divalent radical comprising at least one benzothiazole or benzimidazole linkage
GB9108279D0 (en) * 1991-04-18 1991-06-05 Ucb Sa A method of preparing 1h-benzimidazoles
US5317078A (en) * 1991-10-30 1994-05-31 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Polybenzimidazole via aromatic nucleophilic displacement
FI972090L (fi) 1994-11-17 1997-05-15 Hoffmann La Roche Antibakteeriset dibentsimidatsolijohdannaiset
CN1164227A (zh) * 1994-11-17 1997-11-05 弗·哈夫曼-拉罗切有限公司 联苯并咪唑衍生物
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
JPH11158158A (ja) * 1997-12-03 1999-06-15 Snow Brand Milk Prod Co Ltd 新規ベンゾイミダゾール誘導体
JPH11158156A (ja) 1997-12-03 1999-06-15 Earth Chem Corp Ltd 新規な1−(4−アルキルオキシフェニル)イミダゾール化合物
US6358930B1 (en) 1998-05-28 2002-03-19 Synsorb Biotech Inc. Treatment of C. difficile toxin B associated conditions
JP2000095767A (ja) * 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
GB9908828D0 (en) 1999-04-16 1999-06-16 Univ Reading The Compounds
ATE284874T1 (de) 2000-11-27 2005-01-15 Ciba Sc Holding Ag Substituierte 5-aryl- und 5-heteroaryl-2-(2- hydroxyphenyl)-2h-benzotriazolderivate als uv- absorbierende substanzen
BR0116216A (pt) 2000-12-15 2004-08-17 Vertex Pharma Inibidores de girase e seus usos
FR2819180B1 (fr) 2001-01-11 2003-02-21 Oreal Composition photoprotectrices a base de polymeres amphiphiles d'au moins un monomere a insaturation ethylique a groupement sulfonique et comportant une partie hydrophobe
AU2002228317A1 (en) 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Benz-1,3-azole derivatives and their uses as heparanase inhibitors
CA2445515A1 (en) 2001-05-04 2002-11-04 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
AU2002317377A1 (en) * 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
MXPA04003954A (es) 2001-10-26 2004-11-29 Aventis Pharma Inc Bencimidazoles.
CA2489128C (en) 2002-06-13 2012-01-03 Vertex Pharmaceuticals Incorporated 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
AU2003261834A1 (en) * 2002-08-30 2004-05-04 Bf Research Institute, Inc. Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
JP2006513162A (ja) 2002-11-01 2006-04-20 パラテック ファーマシューティカルズ インコーポレイテッド 転写因子調節化合物およびその使用方法
AU2005324492B2 (en) 2004-04-23 2012-06-07 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
KR100629060B1 (ko) 2004-08-11 2006-09-26 주식회사 엘지화학 새로운 벤즈이미다졸계 화합물
EP1812440B1 (en) 2004-11-04 2010-09-22 Vertex Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
WO2006077412A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Thienopyrroles useful in the treatment of inflammation
US7825154B2 (en) 2005-08-12 2010-11-02 The United States Of America As Represented By The Secretary Of The Army Small molecule inhibitors of botulinum neurotoxins
CN101321744A (zh) 2005-11-07 2008-12-10 沃泰克斯药物股份有限公司 作为回旋酶抑制剂的苯并咪唑衍生物
KR100744827B1 (ko) * 2006-04-05 2007-08-01 한국화학연구원 트리플루오로비닐옥시기를 포함하는 불소계 벤즈이미다졸 단량체 및 이의 제조방법
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
SG174086A1 (en) 2006-08-30 2011-09-29 Cellzome Ltd Triazole derivatives as kinase inhibitors
AR063311A1 (es) 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
WO2008073451A2 (en) 2006-12-11 2008-06-19 Sirtris Pharmaceuticals, Inc. Benzoimidazole derivatives as sirtuin (sir) modulating compounds
EP2121626A1 (en) 2006-12-15 2009-11-25 Pfizer Products Inc. Benzimidazole derivatives
WO2009147189A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
KR101022649B1 (ko) 2008-08-07 2011-03-22 삼성모바일디스플레이주식회사 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
CN102427731B (zh) 2009-02-27 2015-05-13 英安塔制药有限公司 丙型肝炎病毒抑制剂
KR101219487B1 (ko) 2009-03-03 2013-01-15 덕산하이메탈(주) 비스벤조이미다졸 화합물 및 이를 이용한 유기전기소자, 그단말
SI2414369T1 (sl) 2009-04-02 2015-12-31 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Derivati imidazo(2,1-b)(1,3,4)tiadiazola
US8536180B2 (en) 2009-05-27 2013-09-17 Abbvie Inc. Pyrimidine inhibitors of kinase activity
CA2763140A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
JP5744859B2 (ja) 2009-06-15 2015-07-08 ライジェル ファーマシューティカルズ, インコーポレイテッド 脾臓チロシンキナーゼ(syk)の小分子阻害薬
WO2011046954A1 (en) 2009-10-13 2011-04-21 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
SI2575968T1 (sl) 2010-06-01 2016-06-30 Summit Therapeutics Plc Spojine za zdravljenje bolezni, ki je povezana s clostridium difficile

Also Published As

Publication number Publication date
BRPI0922220A8 (pt) 2018-04-03
PL2373631T3 (pl) 2015-10-30
SI2373631T1 (sl) 2015-08-31
JP2012510458A (ja) 2012-05-10
US8975416B2 (en) 2015-03-10
BRPI0922220A2 (pt) 2015-12-29
CN102227411A (zh) 2011-10-26
ZA201103751B (en) 2014-10-29
KR20110093925A (ko) 2011-08-18
RU2525915C2 (ru) 2014-08-20
DK2907813T3 (en) 2016-07-25
HK1208668A1 (en) 2016-03-11
ES2537059T3 (es) 2015-06-02
CY1117934T1 (el) 2017-05-17
SMT201500117B (it) 2015-07-09
EP2907813B1 (en) 2016-04-27
CA2744962A1 (en) 2010-06-10
US9314456B2 (en) 2016-04-19
WO2010063996A3 (en) 2010-12-29
PT2907813T (pt) 2016-08-05
US20160184283A1 (en) 2016-06-30
HK1162169A1 (en) 2012-08-24
EP3095783A1 (en) 2016-11-23
HRP20150518T1 (hr) 2015-07-17
RU2011127165A (ru) 2013-01-10
DK2373631T3 (en) 2015-05-26
HUE029151T2 (hu) 2017-02-28
US20150150861A1 (en) 2015-06-04
LT2907813T (lt) 2016-10-10
AU2009323854A1 (en) 2010-06-10
ES2575908T3 (es) 2016-07-04
MX2011005837A (es) 2011-11-18
CA2744962C (en) 2017-06-06
WO2010063996A2 (en) 2010-06-10
AU2009323854B2 (en) 2014-06-26
EP2373631A2 (en) 2011-10-12
CN102227411B (zh) 2015-10-14
US9763925B2 (en) 2017-09-19
JP5665756B2 (ja) 2015-02-04
KR101643435B1 (ko) 2016-07-27
NZ593111A (en) 2013-05-31
RS54904B1 (sr) 2016-10-31
US20120020950A1 (en) 2012-01-26
HRP20160597T1 (hr) 2016-09-23
SG171939A1 (en) 2011-07-28
EP2907813A1 (en) 2015-08-19
JP2015078220A (ja) 2015-04-23
PT2373631E (pt) 2015-06-09
CY1116383T1 (el) 2017-02-08
IL213325A0 (en) 2011-07-31
AU2009323854A2 (en) 2011-06-30
PL2907813T3 (pl) 2016-09-30
BR122020013025B1 (pt) 2021-05-18
BRPI0922220B1 (pt) 2021-03-09
SI2907813T1 (sl) 2016-09-30
BRPI0922220B8 (pt) 2021-05-25
IL213325A (en) 2016-02-29
EP2373631B1 (en) 2015-02-25
GB0821913D0 (en) 2009-01-07
JP2017048217A (ja) 2017-03-09

Similar Documents

Publication Publication Date Title
SMT201600259B (it) Composizioni farmaceutiche antibatteriche
LTPA2018014I1 (lt) Farmacinė kompozicija 514
LTC2140867I2 (lt) Farmacinė kompozicija
DK3097925T3 (da) Farmaceutisk sammensætning
BRPI0919708A2 (pt) composições antimicrobianas
BRPI1004940A2 (pt) composição farmacêutica
PT2453922T (pt) Composições orais antibacterianas
RU2493831C3 (ru) Фармацевтические композиции
BRPI0721651A2 (pt) Composição farmacêutica
BRPI1012539A2 (pt) composições farmacêuticas
SMT201700095B (is) Composizioni farmaceutiche per inalazione
BRPI1009982A2 (pt) composição antimicrobiana hidratante
DK2034997T3 (da) Antibakterielle sammensætninger
BRPI0920521A2 (pt) combinação farmacêutica
BRPI1015939A2 (pt) composição farmacêutica
DK2285413T3 (da) Farmaceutisk sammensætning
DK2120884T3 (da) Farmaceutisk sammensætning
IT1394400B1 (it) Composizioni farmaceutiche
EP2236149A4 (en) MEDICAL COMPOSITION
EP2373166A4 (en) ANTIMICROBIAL COMPOSITIONS
BRPI0921313A2 (pt) composição farmaucêutica
PT2209464E (pt) Composição farmacêutica antimalárica
BRPI0820198A2 (pt) composições farmacêuticas
BR112012003149A2 (pt) composição farmacêutica
BR112012001340A2 (pt) composições farmacêuticas